LNTH - Lantheus POINT Biopharma receive FDA Fast Track status for prostate cancer candidate
2023-04-24 08:39:37 ET
For further details see:
Lantheus, POINT Biopharma receive FDA Fast Track status for prostate cancer candidateLink your Twitter Account to Market Wire News
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
home / news releases / LNTH - Lantheus POINT Biopharma receive FDA Fast Track status for prostate cancer candidate
Stock Information
Get LNTH Alerts
News, Short Squeeze, Breakout and More Instantly...